Atezolizumab neutralizing assay development: a novel way of evaluating assay cutpoint after sample pretreatment
Abstract Atezolizumab, a biotherapeutic monoclonal antibody directed against PD-L1, has been shown to be efficacious in multiple oncology indications. In clinical trials, a subset of patients developed anti-atezolizumab antibodies, necessitating the development of a neutralizing antibody (NAb) assay...
Saved in:
Main Authors: | Rachel Melendez, Jane Ruppel, Cecilia Leddy, Jenny Yang, Ann Brady, Yenny Webb-Vargas, Jochen Brumm, Lynn Kamen, Yuan Song |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2025-02-01
|
Series: | AAPS Open |
Online Access: | https://doi.org/10.1186/s41120-024-00105-z |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Methodology for Wetland Seedbank Assays
by: Carrie Reinhardt Adams, et al.
Published: (2008-05-01) -
Methodology for Wetland Seedbank Assays
by: Carrie Reinhardt Adams, et al.
Published: (2008-05-01) -
Intestinal Permeability Assays: a Review
by: A. A. Iakupova, et al.
Published: (2021-04-01) -
Missed rifampicin and isoniazid resistance by commercial molecular assays
by: L Richards, et al.
Published: (2024-07-01) -
In Vitro Assay to Examine Osteoclast Resorptive Activity Under Estrogen Withdrawal
by: Cara Fiorino, et al.
Published: (2025-01-01)